Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand.
about
T-cell-based therapies for malignancy and infection in childhood.Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia.High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cellsHarnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy.Transcription suppression of SARI (suppressor of AP-1, regulated by IFN) by BCR-ABL in human leukemia cells.Persistence of transcriptionally silent BCR-ABL rearrangements in chronic myeloid leukemia patients in sustained complete cytogenetic remission.Minor H antigens: genes and peptides.Separating graft-versus-tumor from graft-versus-host reactions.BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia.Molecular genetics of pediatric soft tissue tumors: clinical application.Low-intensity transplant regimens facilitate recruitment of donor-specific regulatory T cells that promote hematopoietic engraftment.Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMTImmune reconstitution following hematopoietic progenitor cell transplantation: challenges for the future.Genetic modification of human T lymphocytes for the treatment of hematologic malignancies.Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effectsA pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas.Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM090The allogeneic graft-versus-cancer effect.Lithothamnion muelleri controls inflammatory responses, target organ injury and lethality associated with graft-versus-host disease in mice.Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation.Antiviral responses following L-leucyl-L-leucine methyl esther (LLME)-treated lymphocyte infusions: graft-versus-infection without graft-versus-host disease.Tyrosine kinase inhibitor STI571 in the treatment of Philadelphia chromosome-positive leukaemia failing myeloablative stem cell transplantation.Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions.Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation.Mesenchymal stem cells for graft-versus-host disease: a double edged sword?Differential cytotoxicity and bystander effect of the rabbit cytochrome P450 4B1 enzyme gene by two different prodrugs: implications for pharmacogene therapy.Antigen-specific targeting of CD8+ T cells with receptor-modified T lymphocytes.Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation.Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant.Ex vivo evaluation of PBMNCs collected with a new cell separator.Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMT.The pathophysiology of acute graft-versus-host disease.Capillary electrophoresis for chimerism monitoring by PCR amplification of microsatellite markers after allogeneic hematopoietic cell transplantation.Amplification of T cells from human cord blood in serum-deprived culture stimulated with stem cell factor, interleukin-7 and interleukin-2.
P2860
Q33750862-8C25304A-65CD-40FE-A021-2BB4E32C8D9CQ33770125-984AC5CC-0ACA-42CA-8D6D-969679DDD73CQ33806895-AC74FF90-6C24-4F82-952B-9D45B3599DCDQ34089112-E74ABB35-DFEC-49E9-A5BA-356217F89EB5Q34213580-309E3F98-DA34-4EBC-87E9-B7D7CB95094EQ34430371-297EA8DB-3C21-412E-8CC2-BEBBF4EBB524Q34553895-28EB5102-D891-4C01-952F-74722BBD34A3Q34769849-FEF4C402-47B4-4FD1-AB03-8C5B2537D00CQ35022511-F3FD21C9-2E6D-4032-93F1-FDCA357D2126Q35183100-DAABC67E-ADB1-4258-A575-977225C3C376Q35850195-D54A7871-42C8-4DDE-90FB-310864DC6C62Q36036334-59C277A8-1030-4FD8-80EA-95FE30DB9778Q36090218-C4A6832D-F833-4345-968E-21CDD9006A10Q36366557-C12625E6-0E90-4CE8-928D-61476A29A04BQ36380188-4B3E64BF-9EDB-41B4-8F3C-EE9E35F1D4B4Q36813562-211AE22E-80F7-4128-BC00-750A7E973F22Q37250169-F4035899-F59F-4BAF-BBEE-9B4A469F9D13Q37593125-10F140A0-1559-4B2C-81B3-98FA7AD7BD42Q39122603-6C84754A-0FFC-4E37-8622-E02B6A37820AQ39966752-3AE08B1F-8549-4B51-BBA9-A87C09BCBCA5Q40593421-7BE052C0-C6E1-44A2-A7F4-8D9C7901FD3AQ41811942-77A5106B-2F2F-4483-8817-13160ABA507FQ44171003-FB2C43A1-EC35-4FA9-9297-083B1211B0F4Q44401517-38380D6B-2FE9-44DA-908B-64C4DBD68B20Q44401538-AD4A1355-2C2F-4992-A9D8-22EB84F75014Q44786836-4D612B7C-64E8-4F0E-B465-436E096FC7A6Q45714279-530707B5-794D-4535-AACA-B6B2754C564FQ45859442-5D225DB5-0146-44DB-A473-9912C14828EAQ46366067-01C52947-CC2B-4955-BA4F-FAFBD3ACAAEFQ46736545-B7E533BB-AF31-44E5-8B92-F12D99E33F6CQ47609376-40E8B1F5-3F4D-418B-8CEA-C70F9538C01BQ49166218-DBB11155-4A58-4C77-8B80-171B99F4F9F1Q53381394-431F198D-3665-4D6F-875D-24408EF3B63CQ53676885-C1F8F400-98CA-41F5-A37E-DF28F8C5DE0EQ54664899-30592414-161C-4BC5-8EE9-65056FF7A37DQ54778744-06A251C9-AA5A-424F-BE84-FD2C25A1CE07
P2860
Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand.
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Donor lymphocyte infusions for ...... ransplant: where we now stand.
@ast
Donor lymphocyte infusions for ...... ransplant: where we now stand.
@en
type
label
Donor lymphocyte infusions for ...... ransplant: where we now stand.
@ast
Donor lymphocyte infusions for ...... ransplant: where we now stand.
@en
prefLabel
Donor lymphocyte infusions for ...... ransplant: where we now stand.
@ast
Donor lymphocyte infusions for ...... ransplant: where we now stand.
@en
P1476
Donor lymphocyte infusions for ...... transplant: where we now stand
@en
P2093
J M Goldman
P304
P356
10.1016/S0301-472X(99)00096-X
P577
1999-10-01T00:00:00Z